FeesSafety
Pluang+

Neflamapimod shows promise in reducing brain damage marker in rare speech-related dementia trial

Company Fundamentals
16 Nov 2026, 23:02 WIB
GlobeNewsWire
View Source
Bullish
Neflamapimod shows promise in reducing brain damage marker in rare speech-related dementia trial

CervoMed presented interim Phase 2a trial data showing that neflamapimod, an oral drug, reduced neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with nonfluent variant primary progressive aphasia (nfvPPA), a rare neurodegenerative disease. Patients with higher plasma levels of the drug showed a reduction in NfL over 24 weeks, indicating potential slowing of disease progression. The drug was well tolerated, and full 24-week data including a higher dose cohort are expected in early 2027. This offers hope for a condition currently lacking approved treatments.

CervoMed's interim data on neflamapimod in neurodegeneration offers context alongside Pluang's health sector snapshot as of Nov 17, 2026 03:31 WIB: Among 150 priced health stocks, 31 rose and 118 fell. Notably, SLS traded at USD 7.36 with a 6.42% drop and a typical hold time of 5 days, contrasting with ARWR at USD 44.78 down 6.28% over 17 days, while SANA held at USD 1.90 with a 6.19% decline and a longer hold time of 27 days, showing varied investor engagement and price movement within the sector.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App